Two trials examined olanzapine and found no difference in the primary outcome ( response to treatment ) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants .
There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms .
BACKGROUND Obsessive compulsive disorder ( OCD ) is a psychiatric disorder which has been shown to affect 2 to 3.5 % of people during their lifetimes .
Inadequate response occurs in 40 % to 60 % of people that are prescribed first line pharmaceutical treatments ( selective serotonin reuptake inhibitors ( SSRIs ) ) .
To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs ( SGAs ) in people suffering from OCD .
OBJECTIVES To evaluate the effects of SGAs ( monotherapy or add on ) compared with placebo or other forms of pharmaceutical treatment for people with OCD .
8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder
The aim of the present pilot study was to investigate in a single-blind manner , over a period of 8 weeks , the comparative efficacy and tolerability of risperidone versus olanzapine addition in the treatment of OCD patients who did not show a > or=35 % decrease in the YBOCS score after 16-week SRI treatment ( defined as resistant ) . The study consisted of two different phases : a 16-week open-label prospect i ve phase to ascertain resistance to SRI treatment and an 8-week single-blind addition phase for resistant subjects only . Ninety-six subjects with DSM-IV OCD ( YBOCS > or=16 ) entered the open-label prospect i ve phase ; at the end of the 16-week period , 50 ( 52 % ) were judged to be resistant and were r and omized to receive risperidone ( 1 to 3 mg/d ) or olanzapine ( 2.5 to 10 mg/d ) addition for 8 weeks . Overall , patients in both groups responded significantly , without differences between the two treatment groups ; although no differences emerged for the proportion of patients reporting at least an adverse event , the profiles of adverse experiences differed significantly , being risperidone associated with amenorrhoea and olanzapine with weight gain
Two trials examined olanzapine and found no difference in the primary outcome ( response to treatment ) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants .
There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms .
BACKGROUND Obsessive compulsive disorder ( OCD ) is a psychiatric disorder which has been shown to affect 2 to 3.5 % of people during their lifetimes .
Inadequate response occurs in 40 % to 60 % of people that are prescribed first line pharmaceutical treatments ( selective serotonin reuptake inhibitors ( SSRIs ) ) .
To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs ( SGAs ) in people suffering from OCD .
OBJECTIVES To evaluate the effects of SGAs ( monotherapy or add on ) compared with placebo or other forms of pharmaceutical treatment for people with OCD .